IPSEN EBIT 2016-2024 | IPSEY

IPSEN EBIT for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • IPSEN 2024 EBIT was 0.537B, a 39.15% decline from 2023.
  • IPSEN 2023 EBIT was 0.883B, a 14.83% increase from 2022.
  • IPSEN 2022 EBIT was 0.769B, a 23.46% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

IPSEN EBIT 2016-2024 | IPSEY

  • IPSEN 2024 EBIT was 0.537B, a 39.15% decline from 2023.
  • IPSEN 2023 EBIT was 0.883B, a 14.83% increase from 2022.
  • IPSEN 2022 EBIT was 0.769B, a 23.46% decline from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.8B
Zoetis (ZTS)$66.8B
Takeda Pharmaceutical (TAK)$46.9B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$31.8B
Sandoz Group AG (SDZNY)$24.6B
Summit Therapeutics (SMMT)$20.5B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.4B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.3B
Orion OYJ (ORINY)$11B
Corcept Therapeutics (CORT)$7.8B
Madrigal Pharmaceuticals (MDGL)$7.7B
Stevanato Group S.p.A (STVN)$7.7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Crinetics Pharmaceuticals (CRNX)$3.1B
Hypermarcas (HYPMY)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
Endo (NDOI)$1.6B